Stents safer than we thought

After sifting the deluge of stent news from Europe over the past few days, experts say that, on balance, drug-coated stents have been avenged. Though the new stents aren't suited to everyone--one study, for instance, showed that drug-eluting stents are more problematic in small blood vessels than in large ones--general benefits outweighed the general risks.

It was just a year ago, you'll recall, that two major studies first raised questions about the safety of drug-coated stents. The follow-up studies won't quash debate completely, especially since the drug-coated versions are more than twice as costly as the bare sort. But they may plug enough holes in the dike to slow the sales decline.

- here's a Johnson & Johnson press release about the follow-up trials
- read here's more from the New York Times

Related stories:
Boston Scientific deals with debt Report
Tough times for stent market  Report
The suit against Boston Scientific Report
J&J makes big cuts at Alza and Scios Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

North Korean hackers were accused of posing as corporate recruiters in a scheme to breach AstraZeneca's computer systems and steal COVID-19 research.

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

McKinsey & Company helped guide Purdue's strategy for years and pitched the idea of rebates to distributors for overdoses, according to the NYT.